Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Next Previous
Trial Profile

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TRAD

Most Recent Events

  • 01 Dec 2023 Results (n=55) assessing whether dasatinib therapy after TFR1 failure post-imatinib discontinuation could improve the likelihood of TFR2 published in the British Journal of Haematology
  • 13 Dec 2022 Results of a risk factor analysis associated with TRF2 failure for treatment-free remission failure with a median follow-up duration of 27.5 months presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 17 Jun 2022 Results assessing treatment-free remission 2 rate after dasatinib discontinuation in patients with chronic myeloid leukaemia, presented at the 27th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top